HbA1c Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global HbA1c Testing Market Trends and Insights

Rising global diabetes prevalence & earlier screening guidelines

Diabetes prevalence is projected to reach 1.31 billion individuals by 2025, intensifying demand for accessible HbA1c testing solutions. Earlier screening recommended by the American Diabetes Association places HbA1c as the primary diagnostic metric, prompting laboratories to expand throughput ^{[2]American Diabetes Association, “Standards of Care in Diabetes 2024,” diabetesjournals.org} . Health systems face rising economic burdens, with the United States spending USD 413 billion on diabetes care in 2022, reinforcing the push for early detection. The World Health Organization includes HbA1c on its Essential Diagnostics List, underscoring its global relevance ^{[3]Ke‐Jie He, "Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021," Frontiers in Endocrinology, frontiersin.org}. Greater awareness in low-income regions is stimulating procurement of cost-efficient test kits suitable for decentralized programs.

Growing uptake of point-of-care HbA1c analyzers in primary care settings

Devices such as the Siemens DCA Vantage deliver results in under 7 minutes, complying with NGSP performance criteria. Real-time feedback improves glycemic control by enabling immediate treatment adjustments. Roche’s cobas b 101 provides finger-stick results in 5 minutes and benefits from Medicare reimbursement, expanding use in family practices. Comparative studies show 76% uptake for capillary HbA1c screening versus 37.5% for venous draws in community programs. Chinese cost-utility analyses confirm favorable economics with incremental ratios below urban and rural willingness-to-pay thresholds.

Expansion of HbA1c-based reimbursement metrics in value-based care contracts

Aetna recorded a 49% rise in members achieving HbA1c control under value-based agreements, saving USD 660 million compared with fee-for-service models. The 2025 Medicare Physician Fee Schedule mandates glycemic status assessment measures within the APP Plus set, supporting widespread test reimbursement. Oregon’s primary care payment model and EmblemHealth incentive programs align provider bonuses to HbA1c outcomes. CPT Category II codes now reimburse documentation activities, encouraging higher testing frequency.

Rapid price declines in microfluidic single-use HbA1c cartridges for LMIC mass-screening

Orange Biomed’s OBM Rapid A1C leverages protein-free microfluidics to lower calibration requirements and reduce per-test cost by 60-70% once regulatory clearance is obtained. Paper-based analytical devices produced through wax printing or inkjet methods further compress prices while sustaining analytical precision. Dried blood spot protocols remain stable for more than 10 days at room temperature, enabling rural outreach programs.

High capital and maintenance cost of HPLC analyzers for small labs

Initial purchase prices range from USD 50,000 to USD 200,000 and annual service contracts can exceed 15% of acquisition cost. CLIA 2024 updates tightened performance targets to ±8%, adding operational complexity for laboratories with limited budgets. Consumable costs, including ion-exchange columns and calibration standards, further strain finances, prompting smaller facilities to shift toward immunoassay analyzers.  

Analytical interference from hemoglobin variants lowering test confidence

Around 7% of the global population carries hemoglobin variants that alter test accuracy. Hemoglobin E underestimates HbA1c using ion-exchange chromatography, common in Southeast Asia. Elevated fetal hemoglobin in sickle cell disease or β-thalassemia affects results at levels as low as 7%, necessitating alternative methodologies or confirmatory testing. FDA regulation 21 CFR 862.1373 requires manufacturers to disclose variant interference and label limitations.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Point-of-care systems accelerate decentralization

Benchtop analyzers accounted for the largest share in 2025, capturing 59.42% of the HbA1c testing market. They remain the backbone of high-throughput laboratories that process thousands of specimens daily. Systems such as Beckman Coulter’s DxC 500 AU accept whole blood without manual preparation, sustaining workflow efficiency. In contrast, handheld devices drive the fastest expansion at a 6.92% CAGR as health services prioritize patient-centric delivery. The Siemens DCA Vantage, which delivers NGSP-traceable results in 6 minutes, exemplifies the reliability that now characterizes decentralized testing.

Growth momentum for handheld formats reflects rising chronic disease management in primary care and retail clinics. Many providers integrate data into electronic health records through middleware solutions, enabling population health analytics and AI-driven decision support. Manufacturers are layering cybersecurity features to comply with data protection regulations while safeguarding wireless connectivity in ambulatory environments. The price curve for single-use test cartridges is trending downward as production scales in Asia, further encouraging adoption among community practitioners and remote outreach programs. Consequently, the HbA1c market is witnessing a dual-track investment pattern where centralized laboratories upgrade high-volume HPLC lines while distributed care sites procure compact analyzers to meet on-the-spot diagnostic needs.

By Technology: Immunoassay platforms narrow the gap

HPLC commanded 61.12% of 2025 revenue, supported by its established accuracy and variant detection. Recent chemistry enhancements, such as ARKRAY’s HA-8160 buffer optimization, have improved precision to coefficients of variation below 1% across 4.4%–17.3% HbA1c ranges. Yet immunoassay systems are posting a 7% CAGR, driven by compatibility with point-of-care devices and lower operator training requirements. The Biolabo Kenza 450TX immunoturbidimetric assay demonstrates strong correlation with HPLC while operating on benchtop photometric analyzers that many small laboratories already use.

Hybrid architectures are emerging. Vendors now ship combined HPLC-immunoassay platforms that auto-route specimens based on sample type, urgency or suspected variant presence. Capillary electrophoresis and MALDI-TOF mass spectrometry occupy niche segments but introduce high sensitivity alternatives for complex hemoglobinopathies. These advances diversify the HbA1c market, allowing laboratories to match technique to clinical requirement, throughput and budget. As immunoassay reagents mature, they are expected to reduce the historical performance gap while maintaining immunity to common hemoglobin variants, thereby sustaining their near-term growth advantage.

By End-User: Homecare gains momentum

Diagnostic and reference laboratories captured 46.87% of the HbA1c market size in 2025, buoyed by established logistics networks and payer contracts. Hospitals also command a sizeable portion as they embed analyzers in core labs and emergency departments. However, homecare settings exhibit the highest 7.05% CAGR. At-home sample collection kits and finger-stick microfluidic devices allow patients to monitor long-term glycemic control without clinic visits. Orange Biomed’s pending OBM Rapid A1C platform highlights this direction, offering laboratory-grade accuracy from a single drop of capillary blood.

Technology convergence supports the homecare surge. Continuous glucose monitoring sensors interface with mobile applications that aggregate daily readings and quarterly HbA1c results. Abbott’s FreeStyle Libre users who combine sensor data with GLP-1 therapies record a 2.4% HbA1c reduction, surpassing medicine alone. Telehealth services integrate these inputs to personalize medication titration and lifestyle coaching, reinforcing adherence. As broadband connectivity and digital literacy improve among older adults, home testing penetration is expected to deepen, solidifying its role as the fastest-growing end-user segment within the HbA1c market.

By Patient Age Group: Older adults steer incremental demand

Adults retained 58.03% share in 2025 due to the high prevalence of type 2 diabetes in working-age populations. Nonetheless, the geriatric cohort is registering the strongest 6.95% CAGR. Longer lifespans and comorbid conditions necessitate frequent glycemic assessment to mitigate cardiovascular and cognitive complications. Diabetes technology adoption among seniors, including insulin pumps and automated insulin delivery, correlates with fewer hypoglycemic events and improved quality of life.

Pediatric testing remains specialized but pivotal. The American Diabetes Association revised guidelines in 2024, recommending targets below 7% HbA1c for children with type 1 diabetes, tightening control thresholds. These stringent targets demand reliable assays with minimal sample volume. Laboratories are therefore validating collection protocols tailored to low-volume pediatric draws.

Geography Analysis

North America maintained leadership with 41.12% revenue share in 2025 as insurers expanded screening coverage and employer wellness programs mandated annual biometric checks. Medicare’s 2024 addition of HbA1c to the diabetes screening benefit notably increased test volumes in federally funded clinics. Europe ranks second, supported by coordinated national diabetes plans across Germany, the United Kingdom and France. Laboratory networks have modernized with integrated LIS-middleware infrastructures to meet ISO 15189 accreditation standards, fostering timely result transmission to primary care teams.

Asia-Pacific is forecast to grow at a 7.13% CAGR, driven by surging prevalence and infrastructure investment. India’s diabetes burden is projected to rise from 74 million cases in 2021 to 124 million by 2045, catalyzing laboratory expansion and point-of-care deployment. China’s urban and rural cost-utility analyses validate the economic logic of decentralized screening, encouraging provincial health budgets to fund pilot programs. Southeast Asian countries are integrating dried blood spot sampling into outreach initiatives to overcome transportation barriers in archipelagic regions, thus broadening test reach.

The Middle East and Africa region faces variant-related analytical complexity. Hemoglobin S and C prevalence requires method selection sensitive to interference profiles, directing some laboratories toward immunoassay or capillary electrophoresis systems. South America experiences steady testing uptick as public health campaigns raise diabetes awareness and private laboratories align their service menus with international guidelines. Across all regions, the HbA1c market is benefiting from policy emphasis on early detection and the broader shift toward value-based healthcare financing.

Regulatory Landscape

HbA1c test systems are regulated as in vitro diagnostics with defined performance and labeling obligations. In the United States, Hemoglobin A1c test systems are Class II devices under FDA 21 CFR 862.1373 and are subject to special controls, including disclosure of hemoglobin-variant interference and associated limitations. Those requirements shape method selection (HPLC vs immunoassay vs enzymatic) and constrain the claims that point-of-care formats can make.

Standardization and laboratory quality frameworks also underpin market access. The ADA Standards of Care (2026) specifies that A1C testing methods should be NGSP-certified and traceable to the DCCT reference assay, which reinforces the role of NGSP certification and ongoing verification. CLIA requirements and proficiency testing participation support routine use in clinical laboratories, and accuracy-based grading in programs such as CAP proficiency testing tightens acceptable performance ranges, increasing compliance emphasis for both central labs and distributed testing networks.

Value Chain Analysis

The HbA1c testing value chain starts with assay chemistry and instrument design and then moves into manufacturing analyzers, cartridges/reagents, calibrators, and controls. From there, the market supplies hospitals, diagnostic and reference laboratories, and decentralized care sites. Major platform suppliers and assay manufacturers (such as Abbott, Bio-Rad, Roche, Siemens Healthineers, and others) pair hardware with recurring consumables, and regulatory expectations for NGSP traceability and variant-interference disclosure affect upstream R&D, verification studies, and labeling decisions.

On the downstream side, procurement typically runs through hospital systems, laboratory networks, and group purchasing channels. Many buyers favor bundled or managed arrangements that include analyzers, reagents, service, and connectivity. Vendor operating models that integrate assays with broader clinical chemistry or digital workflow ecosystems (for example, Roche bundling HbA1c assays with cobas platforms and related informatics) support more durable placements and predictable reagent pull-through, while supply continuity for critical components (such as HPLC columns and resins) remains an operational priority as laboratories balance central high-throughput testing with point-of-care deployment.

Market Opportunities and Future Outlook

One area of current whitespace is end-to-end connectivity for decentralized HbA1c testing, where primary care clinics and retail-style sites need NGSP-aligned quality management plus reliable routing of results into electronic health records and population health workflows. Siemens Healthineers RAPIDComm points to the operational pull for centralized oversight of distributed point-of-care HbA1c analyzers, and payer-side quality measurement frameworks (including Medicare Physician Fee Schedule quality measures that incorporate glycemic status assessment) reinforce demand for standardized reporting and audit-ready data capture.

Another opportunity is the linkage of lab automation with digital diagnostics platforms that reduce manual work while improving data usability for care teams. Roche has continued expanding diagnostic workflows and its digital health ecosystem (navify) to improve laboratory and clinical workflow efficiency, including tighter integration of HbA1c results into broader diabetes management pathways. At the same time, method selection pressure from hemoglobin-variant interference creates space for platforms and assays that document performance across prevalent variants and offer clearer interpretive guidance, particularly in regions with higher hemoglobinopathy prevalence where laboratories must align method choice with local patient demographics and proficiency testing requirements.